1.Early investigational drugs targeting PPAR-alpha for the treatment of metabolic disease

Liu, ZM, Hu, M, Chan     More...

Liu, ZM, Hu, M, Chan, P, Tomlinson, B     Less

EXPERT OPINION ON INVESTIGATIONAL DRUGS[1354-3784], Published 2015, Volume 24, Issue 5, Pages 611-621

收錄情况： WOS SCOPUS

WOS核心合集引用: 44  2023影響因子:  4.9  发表年影響因子:  4.408 

2.An overview of new GLP-1 receptor agonists for type 2 diabetes

Tomlinson, B, Hu, M,     More...

Tomlinson, B, Hu, M, Zhang, Y, Chan, P, Liu, ZM     Less

EXPERT OPINION ON INVESTIGATIONAL DRUGS[1354-3784], Published 2016, Volume 25, Issue 2, Pages 145-158

收錄情况： WOS SCOPUS

WOS核心合集引用: 44  2023影響因子:  4.9  发表年影響因子:  4.030 

3.Investigational glucagon-like peptide-1 agonists for the treatment of obesity

Tomlinson, B, Hu, M,     More...

Tomlinson, B, Hu, M, Zhang, YZ, Chan, P, Liu, ZM     Less

EXPERT OPINION ON INVESTIGATIONAL DRUGS[1354-3784], Published 2016, Volume 25, Issue 10, Pages 1167-1179

收錄情况： WOS SCOPUS

WOS核心合集引用: 17  2023影響因子:  4.9  发表年影響因子:  4.030 

4.Tesamorelin, a human growth hormone releasing factor analogue

Wang, Y, Tomililson,     More...

Wang, Y, Tomililson, B     Less

EXPERT OPINION ON INVESTIGATIONAL DRUGS[1354-3784], Published 2009, Volume 18, Issue 3, Pages 303-310

收錄情况： WOS SCOPUS

WOS核心合集引用: 12  2023影響因子:  4.9  发表年影響因子:  4.218